Sign in
CompletedNo phase

Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
People taking part
19 people enrolled
Started
Oct 2015
Ended
Dec 2023
Type of study
Observational, 3 groups
Treatments tested
  • Influenza vaccine
Record updated
16 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Adults who have received either a combined kidney/stem cell transplant and have achieved chimerism or post-transplant recipients who are maintained on standard immunosuppressive therapy. Additionally, healthy controls of either gender ≥ 18 years of age will also be recruited
  • Subjects must be willing and able to receive the IIV4 and provide blood samples at research visits
  • Subjects must be willing and able to read, understand, and be capable of giving informed consent for prospective enrollment

Who cannot take part

  • Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating. Specific conditions include but are not limited to anemia prohibitive of phlebotomy, coagulopathy or inability to receive the IIV4
  • Subjects less than 18 years of age

Where in United States

  • Northwestern University-Comprehensive Transplant CenterChicago, United States

About the trial

What the trial wants to find out

Influenza infection in solid organ transplant recipients is associated with increased morbidity and mortality compared to non-transplanted controls, due in part to the effects of immunosuppression which is necessary to prevent rejection of the transplanted organ. However, transplant patients are less likely to produce antibodies when vaccinated and when they do, the peak and duration of antibody responses are reduced compared to healthy controls. There are considerable differences in the magnitude of these responses, reflecting variability in individual responses to the influenza vaccine and to the immunosuppression regimen. The investigators hypothesize that chimeric kidney transplant recipients off of immunosuppression will have post vaccine immune responses that are comparable to age and gender matched healthy controls.

The 3 groups in the trial

  • Transplant recipients (Chimeric)

    Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).

    Treatment: Influenza vaccine

  • Transplant recipients (IS)

    Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).

    Treatment: Influenza vaccine

  • Controls

    Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).

    Treatment: Influenza vaccine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 May 2025